{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-006233","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.817038+00:00","generated_at":"2026-05-15T22:40:42.144244+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"UroGen reports FY2025 net loss $153.5M; ZUSDURI launch net sales $15.8M; refinances debt at 8.25%","bullets":["FY2025 revenue $109.8M (+21% YoY); JELMYTO net sales $94M (underlying demand +7%).","ZUSDURI net sales $15.8M in initial launch; 838 activated sites, 102 unique prescribers as of Dec 31, 2025.","Permanent J Code (J9282) effective Jan 1, 2026; launch acceleration expected.","Refinanced existing term loan: $200M funded at 8.25% fixed, new $50M tranche available until June 2027.","2026 guidance: JELMYTO net sales $97-101M; total operating expenses $240-250M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-006233","json":"https://secwatch.observer/filing/0001437749-26-006233.json","markdown":"https://secwatch.observer/filing/0001437749-26-006233.md","text":"https://secwatch.observer/filing/0001437749-26-006233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/0001437749-26-006233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/urgn20260226_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:40:42.144244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}